Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Myasthenia Gravis Treatment Market Between 2025 And 2029?
The myasthenia gravis treatment market size has experienced strong growth in recent years. It is projected to increase from $1.55 billion in 2024 to $1.66 billion in 2025, at a compound annual growth rate (CAGR) of 6.9%. The expansion observed historically can be linked to factors such as cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the introduction of plasma exchange, and patient advocacy.
The myasthenia gravis treatment market is poised for significant expansion in the coming years. Its size is forecast to reach $2.25 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.9%. This projected growth is largely propelled by factors such as biologics and monoclonal antibodies, genetic and precision medicine, novel immune modulators, neuroprotective strategies, and biosimilar medications. Prominent developments expected in the forecast period encompass digital therapeutics, cooperative research efforts, patient-centered approaches, the application of real-world evidence, and ongoing long-term safety monitoring.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp
What Are The Main Drivers Boosting The Myasthenia Gravis Treatment Industry’s Expansion?
The increasing occurrence of myasthenia gravis is anticipated to fuel the expansion of the myasthenia gravis treatment market. Myasthenia gravis is characterized as an autoimmune neuromuscular disorder where individuals suffer from fatigue and weakness in their skeletal muscles. Treating myasthenia gravis involves delivering healthcare services and patient care aimed at combating the disease. Consequently, the rising prevalence of myasthenia gravis is enhancing sales within the myasthenia gravis treatment market. For example, data from January 2022, published by the US-based National Organization for Rare Disorders, indicated that autoimmune myasthenia gravis had an estimated prevalence of 14–40 per 100,000 individuals in the United States. Additionally, an April 2024 report from the American Journal of Managed Care, a US-based peer-reviewed journal, estimated an annual incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years, based on an average of 1,800 annual diagnoses of myasthenia gravis (MG). Ultimately, the growing prevalence of myasthenia gravis is a key driver for the growth of the myasthenia gravis treatment market.
What Are The Different Segment Classifications Within The Myasthenia Gravis Treatment Market?
The myasthenia gravis treatmentmarket covered in this report is segmented –
1) By Treatment: Medication; Surgery; Other Treatments
2) By Medication Type: Cholinesterase Inhibitors; Corticosteroids; Immunosuppressants; Other Medication Types
3) By End-Use: Hospitals; Clinics; Other End-Uses
Subsegments:
1) By Medication: Anticholinesterase Agents; Immunosuppressants; Monoclonal Antibodies; Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis; Intravenous Immunoglobulin (IVIg); Supportive Therapies
Which Market Trends Are Creating New Opportunities In The Myasthenia Gravis Treatment Industry?
A significant trend gaining traction within the myasthenia gravis treatment market involves product innovations. Leading entities active in the myasthenia gravis treatment market are concentrating on creating novel solutions to maintain their competitive standing. As an illustration, in October 2023, UCB Pharma, a pharmaceutical firm based in Belgium, disclosed that the US Food and Drug Administration (FDA) had granted approval for Zilucoplan. This medication is prescribed for adults suffering from generalized myasthenia gravis (gMG) who show positive results for anti-acetylcholine receptor (AChR) antibodies. The approval presents a fresh therapeutic alternative for gMG, a condition defined by muscle weakness stemming from an autoimmune reaction. Notably, ZILBRYSQ is distinguished as a self-administered, daily subcutaneous complement C5 inhibitor. This offers a more convenient choice compared to the conventional intravenous treatments, which have long been the primary approach for managing gMG.
Which Global Market Leaders Are Shaping The Future Of The Myasthenia Gravis Treatment Sector?
Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report
How Is Myasthenia Gravis Treatment Market Demand Varying Across Different Regions?
North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Myasthenia Gravis Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=11980&type=smp
Browse Through More Reports Similar to the Global Myasthenia Gravis Treatment Market 2025, By The Business Research Company
Large Suvs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/large-suvs-global-market-report
Printer Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/printer-global-market-report
Printing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/printing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model